COPD Diagnosis Codes

COPD coding at a glance

This tool can help you find the ICD-10 COPD diagnosis code you’re looking for when prescribing Nebulized BROVANA® (arformoterol tartrate) Inhalation Solution.

COPD coding updates
Transitions from ICD-9 to ICD-10
Bronchitis, not specified as acute or chronic
Bronchitis, not specified as acute or chronic
Simple chronic bronchitis
Simple and mucopurulent chronic bronchitis
Mucopurulent chronic bronchitis
Simple chronic bronchitis
Obstructive chronic bronchitis
Mucopurulent chronic bronchitis
Obstructive chronic bronchitis without exacerbation
Mixed simple and mucopurulent chronic bronchitis
Obstructive chronic bronchitis with acute exacerbation
Unspecified chronic bronchitis



Other chronic bronchitis

Unspecified chronic bronchitis


No equivalent or reorganized into new ICD-10 category

Emphysematous bleb




MacLeod syndrome

Other emphysema
Panlobular emphysema
Chronic airway obstruction not elsewhere classified
Other specified chronic obstructive pulmonary disease
Chronic respiratory conditions due to fumes and vapors
Chronic obstructive pulmonary disease, unspecified


BROVANA is reimbursed under the unique J-code J7605.*

For hospital inpatients and patients residing in skilled nursing facilities, BROVANA may be covered under Medicare Part A or Part D.5,6

*No guarantee of coverage.

Medicare reimbursement guide

Find this information and more in our downloadable guide to the reimbursement of BROVANA under Medicare Part B.

  Download Reimbursement Guide

1.  Centers for Medicare & Medicaid Services. ICD-9 code lookup. Accessed February 5, 2016.
2.  World Health Organization. International statistical classification of diseases and related health problems. 10th Revision. Accessed February 5, 2016.
3.  American Lung Association of Minnesota and the Minnesota COPD Coalition. COPD visit billing codes and services. October 2008.
4.  Centers for Medicare & Medicaid Services. Does Medicare cover my health care & prescription drugs while I’m in a nursing home? Accessed February 5, 2016.
5. Centers for Medicare & Medicaid Services. What part A covers. Accessed February 5, 2016.

Important Safety Information & Indication


Long-acting beta2-adrenergic agonists (LABA) increase the risk of asthma-related death. Data from a large placebo-controlled US study that compared the safety of another long-acting beta2-adrenergic agonist (salmeterol) or placebo added to usual asthma therapy showed an increase in asthma-related deaths in patients receiving salmeterol. This finding with salmeterol is considered a class effect of LABA, including arformoterol, the active ingredient in BROVANA (see WARNINGS). The safety and efficacy of BROVANA in patients with asthma have not been established. All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication (see CONTRAINDICATIONS).

BROVANA is not indicated for the treatment of acute episodes of bronchospasm, ie, rescue therapy, and does not replace fast-acting rescue inhalers. BROVANA should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition. 

BROVANA should not be used in conjunction with other inhaled, long-acting beta2-agonists. BROVANA should not be used with other medications containing long-acting beta2-agonists. Patients who have been taking inhaled short-acting beta2-agonists on a regular basis should be instructed to discontinue their regular use and to use them only for symptomatic relief for acute respiratory symptoms.

All LABA, including BROVANA, are contraindicated in patients with asthma without use of a long-term asthma control medication.

As with other inhaled beta2-agonists, BROVANA can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs, BROVANA should be discontinued immediately and alternative therapy instituted.

BROVANA, like other beta2-agonists, can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, blood pressure, and/or symptoms.

BROVANA should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension; in patients with convulsive disorders or thyrotoxicosis; and in patients who are unusually responsive to sympathomimetic amines.

BROVANA, as with other beta2-agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the action of adrenergic agonists on the cardiovascular system may be potentiated by these agents.

Overall efficacy of BROVANA was maintained throughout the 12-week trial duration. Some tolerance to the bronchodilator effect of BROVANA was observed after 6 weeks of dosing (at the end of the dosing interval), although the FEV1 improvement remained statistically significant. This was not accompanied by other clinical manifestations of tolerance.

The five most common adverse events reported with frequency ≥2% in patients taking BROVANA, and occurring more frequently than in patients taking placebo, were pain (8% vs 5%), chest pain (7% vs 6%), back pain (6% vs 2%), diarrhea (6% vs 4%), and sinusitis (5% vs 4%).

For additional information, please see the full Prescribing Information including Boxed Warning, and Medication Guide for BROVANA (arformoterol tartrate) Inhalation Solution, at

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088.

BROVANA® (arformoterol tartrate) Inhalation Solution is indicated for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. BROVANA is for use by nebulization only.